Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a b...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2020]
|
| In: |
Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 3, Pages: 633-640 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-019-0732-9 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-019-0732-9 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-019-0732-9 
|
| Verfasserangaben: | E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J.T. Bittenbring, S. Robinson, S. Montoto, A. Sureda, P. Dreger on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694676544 | ||
| 003 | DE-627 | ||
| 005 | 20220818042504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200416r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-019-0732-9 |2 doi | |
| 035 | |a (DE-627)1694676544 | ||
| 035 | |a (DE-599)KXP1694676544 | ||
| 035 | |a (OCoLC)1341315128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Domingo-Domènech, Eva |e VerfasserIn |0 (DE-588)1208420607 |0 (DE-627)169467777X |4 aut | |
| 245 | 1 | 0 | |a Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma |b a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |c E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J.T. Bittenbring, S. Robinson, S. Montoto, A. Sureda, P. Dreger on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| 264 | 1 | |c [2020] | |
| 300 | |b Diagramme | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 6 November 2019 | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 520 | |a Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Boumendil, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Climent, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Socié, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kroschinsky, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finel, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vandenbergue, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nemet, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stelljes, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bittenbring, J. T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Robinson, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montoto, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sureda, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 55(2020), 3, Seite 633-640 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:3 |g pages:633-640 |g extent:8 |a Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-019-0732-9 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-019-0732-9 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200416 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 14 |y j | ||
| 999 | |a KXP-PPN1694676544 |e 362408139X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Domingo-Domènech","given":"Eva","role":"aut","display":"Domingo-Domènech, Eva"},{"role":"aut","given":"A.","display":"Boumendil, A.","family":"Boumendil"},{"display":"Climent, F.","role":"aut","given":"F.","family":"Climent"},{"role":"aut","given":"G.","display":"Socié, G.","family":"Socié"},{"display":"Kroschinsky, F.","role":"aut","given":"F.","family":"Kroschinsky"},{"given":"H.","role":"aut","display":"Finel, H.","family":"Finel"},{"family":"Vandenbergue","display":"Vandenbergue, E.","given":"E.","role":"aut"},{"display":"Nemet, D.","role":"aut","given":"D.","family":"Nemet"},{"given":"M.","role":"aut","display":"Stelljes, M.","family":"Stelljes"},{"given":"J. T.","role":"aut","display":"Bittenbring, J. T.","family":"Bittenbring"},{"given":"S.","role":"aut","display":"Robinson, S.","family":"Robinson"},{"display":"Montoto, S.","role":"aut","given":"S.","family":"Montoto"},{"display":"Sureda, A.","given":"A.","role":"aut","family":"Sureda"},{"display":"Dreger, Peter","role":"aut","given":"Peter","family":"Dreger"}],"name":{"displayForm":["E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J.T. Bittenbring, S. Robinson, S. Montoto, A. Sureda, P. Dreger on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation"]},"note":["Published online: 6 November 2019","Gesehen am 16.04.2020"],"relHost":[{"note":["Gesehen am 17.01.25"],"id":{"issn":["1476-5365"],"zdb":["2004030-1"],"eki":["320433366"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationBone marrow transplantation","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320433366","origin":[{"publisherPlace":"London ; Basingstoke ; London","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedKey":"1997"}],"language":["eng"],"part":{"issue":"3","extent":"8","pages":"633-640","text":"55(2020), 3, Seite 633-640","year":"2020","volume":"55"},"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"pubHistory":["Nachgewiesen 19.1997 -"]}],"physDesc":[{"extent":"8 S.","noteIll":"Diagramme"}],"id":{"doi":["10.1038/s41409-019-0732-9"],"eki":["1694676544"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[2020]"}],"recId":"1694676544","language":["eng"],"title":[{"subtitle":"a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","title":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma","title_sort":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma"}]} | ||
| SRT | |a DOMINGODOMALLOGENEIC2020 | ||